Live Breaking News & Updates on Jm financial research

Stay informed with the latest breaking news from Jm financial research on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Jm financial research and stay connected to the pulse of your community

india vs global peers: Indian stock market decoupling has begun. 3 reasons why it will last

Indias economic and earnings growth strength, coupled with a possible recession in the US are the two key reasons behind Indias outperformance and we are hopeful that this outperformance should continue due to 3 reasons.

India , Japan , Japanese , Nasdaq , India-inc , Bloomberg , Jm-financial-research , Japanese-nikkei , Indian-economic , Indian-equity , India-vs-global-peers

Strong order book, diversified portfolio drive Street's confidence in TCS

The Street shrugged off a muted first quarter of financial year 2023-24 (Q1FY24) and a cautious near-term outlook by India's largest information technology (IT) services company, Tata Consultancy Services (TCS).

The stock was the top Nifty50 and Sensex gainer on Thursday, rising 2.5 per cent, as investors took comfort from a robust order book and an encouraging pipeline.

Like its larger peer, HCL Technologies' (HCL Tech), too fell short of the Street's expectations on the revenue and margin fronts given cuts in discretionary expenditure.

India , Abhishek-kumar , Kumar-rakesh , Anuj-kotewar , Wipro , Tata-consultancy-services , Paribas-research , Jm-financial-research ,

Pharma stocks rally on lower price erosion, hopes of US generic mkt uptick

The BSE Healthcare Index is up 19 per cent as compared to BSE Sensex returns of 11 per cent during this period.

Nitin Agarwal of DAM Capital highlighted this trend in a report last month.

'After a sustained period of underperformance over FY21-23, the BSE Healthcare Index has once again captured the spotlight.

'The recent uptick in performance has been driven by hospitals and emerging green shoots in pharmaceutical exports, particularly to the US, along with sustaining momentum in domestic branded formulations,' he said.

Sun-pharma , Nitin-agarwal , Aurobindo-pharma , Zydus-lifesciences , Uttam-ghosh-rediff , Jm-financial-research , Nomura-research , Drug-administration , Cipla , Zydus-life , Torrent-pharma , Bino-pathiparampil

Ashok Leyland shares extend gains, jump 7% today to trade near one-year high; here's what brokerages say

Ashok Leyland share price: The stock today soared 6.64 per cent to hit a day high of Rs 167.80, just 0.95 per cent shy away from its 52-week high price of Rs 169.40, a level seen on September 6, 2022. The counter has gained 12.08 per cent in 2023 so far and 28.26 per cent in the past one year.

Prabhudas-lilladher , Jm-financial-research , Ashok-leyland , Light-commercial-vehicle , Heavy-commercial-vehicle-segment , Commercial-vehicle ,

Shift to new norms may hamper growth, margins for Cummins India in FY24

Over the past three trading sessions, the stock of Cummins India has gained about nine per cent on strong January-March quarter (Q4) results and good near-term prospects.

Its Q4 performance was led by a healthy 29 per cent revenue growth over the year ago quarter.

This was largely on the back of a 33 per cent jump in domestic revenues while exports witnessed a growth of 17 per cent.

Subhadip-mitra , Neelotpal-sahu , Dhirendra-tiwari , Priyankar-biswas , Jm-financial-research , Cummins-inc , Nomura-research , Nuvama-research , Cummins-india , Central-pollution-control-board , Stock-broking , Business-news

RIL lags as markets near new highs; investors fret over rising debt

Reliance Industries (RIL) was the top-performing index stock on Friday (May 26) and closed the day with gains of 2.8 per cent, against a 1 per cent rise in the benchmark S&P BSE Sensex during the day.

RIL's performance on the bourses on Friday was, however, an exception, and the stock has struggled to beat the broader market for nearly two years now.

The company's share price is currently at the same level as in September 2021, while the benchmark index is up 6 per cent in the period.

Hindustan , India-general- , India , Dayanand-mittal , Krishna-kant , Dimel-francis , Jm-financial-research , Bajaj-auto , Reliance-industries , Hindustan-unilever , Jio-platforms , Business-news

Weak sales growth weighs on Avenue Supermarts, operational parameters weak

The stock of the retail chain Avenue Supermarts (Dmart) was the biggest loser in the BSE 100 Index shedding 4.35 per cent on Thursday and added to these losses on Monday by falling an additional 1.3 per cent.

The Street was reacting to lower than expected operational performance by the company in the March quarter.

The country's largest listed retailer by market capitalisation reported a 20 per cent year-on-year (y-o-y) growth in its top line to Rs 10,337 crore.

Supermarts-dmart , Shubhangi-nigam , Garima-mishra , Motilal-oswal-research , Kotak-research , Prabhudas-lilladher-research , Jm-financial-research , Citi-research , Avenue-supermarts , Institutional-equities , Prabhudas-lilladher , D-mart-ready

Weak sales growth weighs on Avenue Supermarts, operational parameters weak

Agencies The stock of the retail chain Avenue Supermarts (Dmart) was the biggest loser in the BSE 100 Index shedding 4.35 per cent on Thursday and added to these losses on Monday by falling an additional 1.3 per cent. The Street was reacting to lower than expected operational performance by the company in the

Supermarts-dmart , Shubhangi-nigam , Garima-mishra , Citi-research , Jm-financial-research , Avenue-supermarts , Institutional-equities ,

'Sun Pharma offers the best medium- to long-term earnings growth visibility'

India's largest listed pharmaceutical (pharma) company - Sun Pharmaceutical Industries (Sun Pharma) - is expected to maintain its outperformance vis-à-vis the sector's, as its multiple bets on specialty products, improving product mix, recent acquisitions, and branded business are finding favour with brokerages.

While it has gained 7 per cent over the past year, the Nifty Pharma Index is down 13.6 per cent.

Its outperformance over two years has been fairly evident, with the market leader gaining 66 per cent to Nifty Pharma's minus 1.4 per cent.

India , Halol , Gujarat , Alok-dalal , Sun-pharma , Tarun-shetty , Dhawal-khut , Jefferies-research , Cipla , Sun-pharmaceutical-industries-pharma , Concert-pharmaceuticals-inc , Jm-financial-research

Muhurat Trading Picks 2022 by Top Stock Brokers

Muhurat Trading Picks 2022 by Top Stock Brokers
stockmaniacs.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from stockmaniacs.net Daily Mail and Mail on Sunday newspapers.

Hindustan , India-general- , India , Apis-fdfs , Axis-bank , Mahindra , Jm-financial-services , Titan-industries , Jm-financial-research , Computer-age-management-services , Hindustan-unilever-ltd , City-union-bank